Shots:

• The companies collaborated to initiate a P-III trial to evaluate the safety & efficacy of INO-4800 (2.0mg- two-dose regimen- given at a gap of 1 mos.) in healthy men & non-pregnant women aged ≥18yrs. with COVID 19 across Latin American & Asia. The study expected to commence in summer across the globe
• The 1EPs of the trial will be virologically confirmed COVID-19 disease. The P-II data showed that the therapy was well-tolerated & immunogenic in all tested age groups
• Under the expanded collaboration- Advaccine get rights to additional Asian countries outside of Greater China

  | Ref: PR Newswire | Image: Inovio